CALTH. Inc Logo

CALTH. Inc

Develops AI-powered rapid diagnostic solutions for point-of-care and self-testing.

402420 | KO

Overview

Corporate Details

ISIN(s):
KR7402420004
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로 54, 321호(시흥동, 기업성장센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

CALTH Inc. is an in vitro diagnostics (IVD) company that develops and manufactures rapid diagnostic solutions. The company provides innovative healthcare services for point-of-care testing (POCT), self-testing, and precision medicine. Its core business is built upon two proprietary technologies: an "Engineered Nanotrap" system for high-sensitivity sample preprocessing and a deep learning-based algorithm for the rapid and accurate analysis of Lateral Flow Assay products. CALTH's mission is to improve quality of life by delivering fast, accurate, and low-cost diagnostic tools. The company operates in facilities certified with KGMP and ISO 13485:2016.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-08-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 82.8 KB
2025-08-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 88.1 KB
2025-08-06 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-29 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 35.1 KB
2025-07-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.2 KB
2025-07-17 00:00
Capital/Financing Update
주요사항보고서(전환사채권발행결정)
Korean 54.6 KB
2025-06-19 00:00
Regulatory News Service
기업설명회(IR)개최결과
Korean 6.8 KB
2025-03-31 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 16.4 KB
2025-03-21 00:00
Audit Report / Information
감사보고서제출
Korean 10.1 KB
2025-03-21 00:00
Annual Report
사업보고서 (2024.12)
Korean 971.9 KB
2025-03-14 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 103.1 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 7.5 KB
2025-02-06 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 5.8 KB

Automate Your Workflow. Get a real-time feed of all CALTH. Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for CALTH. Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for CALTH. Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Chemomab Therapeutics Ltd. Logo
Develops antibody drugs neutralizing CCL24 for severe fibro-inflammatory diseases.
United States of America
CMMB
CHINA PHARMA HOLDINGS, INC. Logo
Develops, manufactures, and sells prescription, OTC, and nutritional products for human use.
United States of America
CPHI
China SXT Pharmaceuticals, Inc. Logo
Researches, produces, and sells advanced Traditional Chinese Medicine (TCM) herbal products.
United States of America
SXTC
ChoA Pharmaceutical Co., LTD. Logo
Global manufacturer of OTC medicines and health supplements distributed through pharmacies.
South Korea
034940
CHUGAI PHARMACEUTICAL CO., LTD. Logo
An R&D pharma leader in Japan creating innovative drugs via antibody engineering technology.
Japan
4519
Cinclus Pharma Holding AB Logo
Clinical-stage pharma developing a next-gen P-CAB drug for severe GERD patients.
Sweden
CINPHA
Cingulate Inc. Logo
Developing once-daily, precision timed-release drugs for ADHD and anxiety.
United States of America
CING
Circio Holding ASA Logo
Developing circular RNA vector tech and immunotherapies for gene and cell therapies.
Norway
CRNA
CITIUS ONCOLOGY, INC. Logo
Commercializing LYMPHIR™, an FDA-approved targeted therapy for cutaneous T-cell lymphoma.
United States of America
CTOR
Citius Pharmaceuticals, Inc. Logo
Late-stage biopharma developing critical care products for oncology, infections, and stem cells.
United States of America
CTXR

Talk to a Data Expert

Have a question? We'll get back to you promptly.